DBV Technologies S.A. Stock News

Montrouge, France, June 16, 2022

The French biotech kept its upward momentum going with news of nearly $200 million in fresh funding.

Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

Its peanut allergy patch tests quite well in very young patients.

HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percen

DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint.  Viaskin Peanut demonstrated a

Check these three penny stocks out for your watchlist The post Penny Stocks to Buy With Gains in After Hours? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Are these penny stocks on your watchlist right now? The post Hot Penny Stocks You Need to Know About This Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

DBV Technologies S.A. (NASDAQ:DBVT ) Q1 2022 Results Conference Call May 2, 2022 5:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben -

Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer''s 32nd Annual Healthcare Conference DBV Technologies (GREY: DBVTF ), a clinical-stage biopharmaceutical company, today announced that Dr. Pharis Mohideen, Chief Medical Officer, will present at the Oppenheimer''s 32nd Annual Healthcare Conference on Thursday, March 17 th at 10:00 a.m. ET. A webcast of the presentation may be accessed by visiting the Investors & Media section of the DBV Technologies website at https://www.dbvtechnologies.com/investor-relations/ . An archived replay of the webcast … Full story available on Benzinga.com

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

Atreca (BCEL) +20%. Alignment Healthcare (ALHC) +16%. DBV Technologies DBVT -22%. Ocugen OCGN -20%.

Ocugen OCGN -27% after request for pediatric use of COVID-19 vaccine rejected by FDA.Smith & Wesson Brands SWBI -21% on Q3 earnings release.DBV Technologies DBVT -21% on FY…